Bibliography
- Mangiapane S, Hoer A, Gothe H, et al. Higher persistency with i.v. bisphosphonates in patients with bone metastases [abstract]. J Clin Oncol 2006;24(18S):18623
- Lipton A. Emerging role of bisphosphonates in the clinic: antitumor activity and prevention of metastasis in bone. Cancer Treat Rev 2008;34:S25-30
- Gnant M, Mlineritsch B, Schippinger W, et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med 2009;360:579-91
- Goldhirsch A, Glick JH, Gelber RD, et al. Meeting highlights: International consensus panel of the treatment of primary breast cancer: 7th international conference on adjuvant therapy of primary breast cancer. J Clin Oncol 2001;19:3817-27
- Forbes JF, Cuzick J, Bursdar A, et al.; ATAC Trialists' Group. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol 2008;9:45-53
- Gnant MF, Mlineritsch B, Luschin-Ebengreuth G, et al. Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer – a report from the Austrian Breast and Colorectal Cancer Study Group. J Clin Oncol 2007;25:820-8
- Gnant MF, Mlineritsch B, Luschin-ebengreuth G, et al. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy. Lancet Oncol 2008;9:840-9
- Vordos D, Paule B, Vacherot F, et al. Docetaxel and zoledronic acid in patients with metastatic hormone-refractory prostate cancer. BJU Int 2004;94:524-7
- Avilés A, Nambo MJ, Neri N, et al. Antitumor effect of zoledronic acid in previously untreated patients with multiple myeloma. Med Oncol 2007;24:227-30
- Rack BK, Jueckstock J, Genss EM, et al. Effect of zoledronate on persisting isolated tumor cells in the bone marrow of patients without recurrence of early breast cancer. Presented at the 30th Annual San Antonio Breast Cancer Symposium (SABCS), 13-16 Dec San Antonia, 2007. [poster]
- Available from: http://clinicaltrials.gov/ct2/show/NCT00072020?term=azure&rank=1 [Accessed 7 July 2009]
- Available from: http://www.cancerhelp.org.uk/trials/trials/trial.asp?freetextsearch=bisphosphonate&searchtype=&trial=18954& trialno=11273&spage=1&objective=0& cancer=0&stage=0&phase=0&treatment= 0&location=0 [Accessed 20 May 2009]
- Available from: http://clinicaltrials.gov/ct2/show/NCT00512993?term=zoledronic+acid+cancer&rank=3 [Accessed 3 July 2009]
- Migliorati CA, Schubert MM, Peterson DE, Seneda LM. Bisphosphonate-associated osteonecrosis of mandibular and maxillary bone: an emerging oral complication of supportive cancer therapy. Cancer 2005;104:83-93
- Merigo E, Manfredi M, Meleti M, et al. Bone necrosis of the jaws associated with bisphosphonate treatment: a report of twenty-nine cases. Acta Biomed 2006;77:109-17
- Hoff AO, Toth BB, Altundag K, et al. Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. J Bone Miner Res 2008;23:826-38
- Dimopoulos MA, Kastritis E, Bamia C, et al. Reduction of osteonecrosis of the jaw (ONJ) after implantation of preventive measures in patients with multiple myeloma treated with zoledronic acid. Ann Oncol 2009;20:117-20
- Khan AA, Sándor GK, Dore E, et al. Canadian consensus practice guidelines for bisphosphonate associated osteonecrosis of the jaw. J Rheumatol 2008;35: 1391-7